Pityriasis alba: toward an effective treatment

• Published in: The Journal of dermatological treatment 2022-05, Vol.33 (4), p.2285-2289
• Main Authors: Abdel-Wahab, Hossam M., Ragaie, Maha H.
• Format: Article
• Language: English
• Subjects: calcipotrial; Pityriasis alba; point counting planimetry; tacrolimus; topical steroid
• ISSN: 0954-6634; 1471-1753
• DOI: 10.1080/09546634.2021.1959014

Pityriasis alba is a common skin condition that may be challenging to treat, especially in patients with darker skin type where the hypopigmentation may be more noticeable and represents a major cosmetic concern. This study aims to evaluate the efficacy of three cost-effective treatments of PA in comparison with placebo. This prospective study was conducted on 80 patients complaining from PA and divided into 4 equal groups according the received topical treatment on the target lesions twice daily for 8 weeks (Calcipotriol 0.005% cream, Tacrolimus 0.03% ointment, topical corticosteroid; Clobetasone butyrate 0.05% cream and Petrolatum as Placebo). Clinical evaluation, Physician Global Assessment, Patient's satisfaction levels as well as point counting planimetry were done for evaluation of the response. Significant improvement of scaling and erythema within 3 weeks after initiation of therapy and hypopigmentation by the 8th week, except for those received placebo. Tarolimus 0.03% ointment showed simple superiority over both Calcipotriol 0.005% cream and topical corticosteroid as regards repigmenation, although, the later received the highest level of patient satisfaction. The three treatments were superior to placebo with relative superiority to Tacrolimus 0.03% due to limited side effects.